Who are we?

Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets — FASN, THR-β and FXR — and three combination therapies.

For more information, please view: Gannex Corporate Presentation.pdf

Contact us


  • pr@gannexpharma.com

  • ir@gannexpharma.com

  • hr@gannexpharma.com